These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 8822936)

  • 1. Characterization of primitive subpopulations of normal and leukemic cells present in the blood of patients with newly diagnosed as well as established chronic myeloid leukemia.
    Petzer AL; Eaves CJ; Lansdorp PM; Ponchio L; Barnett MJ; Eaves AC
    Blood; 1996 Sep; 88(6):2162-71. PubMed ID: 8822936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BCR/ABL-negative primitive progenitors suitable for transplantation can be selected from the marrow of most early-chronic phase but not accelerated-phase chronic myelogenous leukemia patients.
    Verfaillie CM; Bhatia R; Miller W; Mortari F; Roy V; Burger S; McCullough J; Stieglbauer K; Dewald G; Heimfeld S; Miller JS; McGlave PB
    Blood; 1996 Jun; 87(11):4770-9. PubMed ID: 8639848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective expansion of primitive normal hematopoietic cells in cytokine-supplemented cultures of purified cells from patients with chronic myeloid leukemia.
    Petzer AL; Eaves CJ; Barnett MJ; Eaves AC
    Blood; 1997 Jul; 90(1):64-9. PubMed ID: 9207439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BCR-ABL expression in different subpopulations of functionally characterized Ph+ CD34+ cells from patients with chronic myeloid leukemia.
    Maguer-Satta V; Petzer AL; Eaves AC; Eaves CJ
    Blood; 1996 Sep; 88(5):1796-804. PubMed ID: 8781437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spontaneous exodus of high numbers of normal early progenitor cells (Ph-negative LTC-IC) in the peripheral blood of patients with chronic myeloid leukaemia at the beginning of the disease.
    Podestà M; Piaggio G; Sessarego M; Pitto A; Benvenuto F; Vassallo F; Fugazza G; Carella AM; Frassoni F
    Br J Haematol; 1997 Apr; 97(1):94-8. PubMed ID: 9136946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phenotypic heterogeneity of primitive leukemic hematopoietic cells in patients with chronic myeloid leukemia.
    Udomsakdi C; Eaves CJ; Lansdorp PM; Eaves AC
    Blood; 1992 Nov; 80(10):2522-30. PubMed ID: 1384787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose hydroxyurea plus G-CSF mobilize BCR-ABL-negative progenitor cells (CFC, LTC-IC) into the blood of newly diagnosed CML patients at any time of hematopoietic regeneration.
    Petzer AL; Hochenburger E; Haun M; Duba HCh; Grünewald K; Hoflehner E; Sill H; Linkesch W; Gastl G; Gunsilius E
    J Hematother Stem Cell Res; 2002 Apr; 11(2):293-300. PubMed ID: 11983100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid decline of chronic myeloid leukemic cells in long-term culture due to a defect at the leukemic stem cell level.
    Udomsakdi C; Eaves CJ; Swolin B; Reid DS; Barnett MJ; Eaves AC
    Proc Natl Acad Sci U S A; 1992 Jul; 89(13):6192-6. PubMed ID: 1631107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BCR/ABL-negative progenitors are enriched in the adherent fraction of CD34+ cells circulating in the blood of chronic phase chronic myeloid leukemia patients.
    Grand FH; Marley SB; Chase A; Titley I; Healy L; Spencer A; Reiter A; Goldman JM; Gordon MY
    Leukemia; 1997 Sep; 11(9):1486-92. PubMed ID: 9305602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selection of myeloid progenitors lacking BCR/ABL mRNA in chronic myelogenous leukemia patients after in vitro treatment with the tyrosine kinase inhibitor genistein.
    Carlo-Stella C; Dotti G; Mangoni L; Regazzi E; Garau D; Bonati A; Almici C; Sammarelli G; Savoldo B; Rizzo MT; Rizzoli V
    Blood; 1996 Oct; 88(8):3091-100. PubMed ID: 8874208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The biology of normal and neoplastic stem cells in CML.
    Eaves C; Udomsakdi C; Cashman J; Barnett M; Eaves A
    Leuk Lymphoma; 1993; 11 Suppl 1():245-53. PubMed ID: 8251904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic myelogenous leukemia primitive hematopoietic progenitors demonstrate increased sensitivity to growth factor-induced proliferation and maturation.
    Bhatia R; Munthe HA; Williams AD; Zhang F; Forman SJ; Slovak ML
    Exp Hematol; 2000 Dec; 28(12):1401-12. PubMed ID: 11146162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of the tyrosine kinase inhibitor AG957 and an Anti-Fas receptor antibody on CD34(+) chronic myelogenous leukemia progenitor cells.
    Carlo-Stella C; Regazzi E; Sammarelli G; Colla S; Garau D; Gazit A; Savoldo B; Cilloni D; Tabilio A; Levitzki A; Rizzoli V
    Blood; 1999 Jun; 93(11):3973-82. PubMed ID: 10339507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leukemic burden in subpopulations of CD34+ cells isolated from the mobilized peripheral blood of alpha-interferon-resistant or -intolerant patients with chronic myeloid leukemia.
    Van den Berg D; Wessman M; Murray L; Tong J; Chen B; Chen S; Simonetti D; King J; Yamasaki G; DiGiusto R; Gearing D; Reading C
    Blood; 1996 May; 87(10):4348-57. PubMed ID: 8639795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aryl hydrocarbon receptor (AHR) is a novel druggable pathway controlling malignant progenitor proliferation in chronic myeloid leukemia (CML).
    Gentil M; Hugues P; Desterke C; Telliam G; Sloma I; Souza LEB; Baykal S; Artus J; Griscelli F; Guerci A; Johnson-Ansah H; Foudi A; Bennaceur-Griscelli A; Turhan AG
    PLoS One; 2018; 13(8):e0200923. PubMed ID: 30091999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Favorable therapeutic index of a p210(BCR-ABL)-specific tyrosine kinase inhibitor; activity on lineage-committed and primitive chronic myelogenous leukemia progenitors.
    Kasper B; Fruehauf S; Schiedlmeier B; Buchdunger E; Ho AD; Zeller WJ
    Cancer Chemother Pharmacol; 1999; 44(5):433-8. PubMed ID: 10501919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Normal and leukemic SCID-repopulating cells (SRC) coexist in the bone marrow and peripheral blood from CML patients in chronic phase, whereas leukemic SRC are detected in blast crisis.
    Sirard C; Lapidot T; Vormoor J; Cashman JD; Doedens M; Murdoch B; Jamal N; Messner H; Addey L; Minden M; Laraya P; Keating A; Eaves A; Lansdorp PM; Eaves CJ; Dick JE
    Blood; 1996 Feb; 87(4):1539-48. PubMed ID: 8608245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection and characterization of primitive malignant and normal progenitors in patients with acute myelogenous leukemia using long-term coculture with supportive feeder layers and cytokines.
    Ailles LE; Gerhard B; Hogge DE
    Blood; 1997 Oct; 90(7):2555-64. PubMed ID: 9326221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phenotypic and functional characterization of long-term culture-initiating cells present in peripheral blood progenitor collections of normal donors treated with granulocyte colony-stimulating factor.
    Prosper F; Stroncek D; Verfaillie CM
    Blood; 1996 Sep; 88(6):2033-42. PubMed ID: 8822922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon-alpha-treated patients with chronic myelogenous leukemia show BCR/ABL-positive peripheral blood progenitor cells surviving long-term culture.
    Schultheis B; Heissig B; Pasternak G; Hörner S; Hehlmann R
    Folia Biol (Praha); 2000; 46(6):251-5. PubMed ID: 11140858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.